Antigenics Inc. (New York): Data from Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine in Glioma Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN FRANCISCO--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) today announced that follow-up data from a Phase 1/2 investigator-sponsored trial of the company’s investigational cancer vaccine Oncophage® (vitespen) in recurrent, high-grade glioma showed that 11 out of 12 patients exceeded the historical median benchmark of 6.5 months survival from time of recurrence. The results from the investigator-initiated National Institutes of Health–sponsored study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco (UCSF), were presented at the International Conference on Molecular Targets and Cancer Therapeutics, jointly sponsored by the American Association for Cancer Research, National Cancer Institute and European Organization for Research and Treatment of Cancer (AACR-NCI-EROTC; abstract # 963).

Back to news